1207175-07-2

Basic information

• Product Name: 3-ethenyloxetan-3-ol
• Synonyms: 3-ethenyloxetan-3-ol;3-Vinyloxetan-3-ol
• CAS NO: 1207175-07-2
• Molecular Formula: C5H8O2
• Molecular Weight: 100.12
• Mol File: 1207175-07-2.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 3-ethenyloxetan-3-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 3-ethenyloxetan-3-ol(1207175-07-2)
• EPA Substance Registry System: 3-ethenyloxetan-3-ol(1207175-07-2)

Safety Data

• Hazardous Substances Data: 1207175-07-2(Hazardous Substances Data)

Usage

Uses

Used in Flavoring and Fragrance Industry:
3-Ethenyloxetan-3-ol is used as a flavoring agent and fragrance for its fruity scent, adding to the sensory appeal of food products and cosmetics.
Used in Pharmaceutical Synthesis:
3-Ethenyloxetan-3-ol is utilized as a key intermediate in the synthesis of various pharmaceuticals, contributing to the development of new drugs and medicinal compounds.
Used in Organic Compound Synthesis:
3-ethenyloxetan-3-ol serves as a building block in the synthesis of other organic compounds, playing a crucial role in the creation of a wide range of chemical products.
Safety Note:
Due to its highly flammable nature, 3-ethenyloxetan-3-ol requires careful handling and storage to prevent accidents and ensure safe usage in all applications.

Upstream product

• 6704-31-0 oxetan-3-one 
• 1826-67-1 vinyl magnesium bromide 

Relevant articles and documents

SUBSTITUTED IMIDAZOLECARBOXYLATE DERIVATIVES AND THE USE THEREOF

A compound is shown in formula (I). The derivatives of the compound include a stereoisomer, a pharmaceutically acceptable salt, a solvate, a prodrug, a metabolite, a deuterated derivative. The compound is a structurally novel substituted imidazole formate derivative. Substituted imidazole formate derivatives are used in preparing a drug with sedative, hypnotic and/or anesthetic effects, as well as a drug that can control the state of epilepsy. The compound has a good inhibitory effect on the central nervous system, and provides a new option for clinical screening of and/or preparation of a drug with sedative, hypnotic and/or anesthetic effects and controlling the state of epilepsy.

HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS

Disclosed are compounds of Formula (I) Formula(I) or salts thereof, wherein HET is a heteroaryl selected from oxazolyl, pyrazolyl, imidazo[l,2-b]pyridazin-3-yl, and pyrazolo[l,5-a]pyrimidin-3-yl, wherein said heteroaryl is attached to the pyridinyl group in the compound of Formula (I) by a carbon ring atom in the heteroaryl and wherein said heteroaryl is substituted with zero to 2 Rb; and R1, R3, and Rb are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.

HETEROARYL SUBSTITUTED NICOTINAMIDE COMPOUNDS

Disclosed are compounds of Formula (I) or salts thereof, wherein: HET is a heteroaryl selected from pyrazolyl, indolyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[2,3-d]pyrimidinyl, pyrazolo[3,4-b]pyridinyl, pyrazolo[3,4-d]pyrimidinyl, 2,3-dihydro-1H-pyrrolo[2,3-b]pyridinyl, imidazo[4,5-b]pyridinyl, and purinyl, wherein said heteroaryl is substituted with Ra and Rb; and R1 and R2 are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases.